HC Wainwright & Co. Maintains Buy on BioLine Rx, Raises Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis maintains a 'Buy' rating on BioLine Rx (NASDAQ:BLRX) and raises the price target from $19 to $21.
September 15, 2023 | 10:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioLine Rx's price target has been raised from $19 to $21 by HC Wainwright & Co., maintaining a 'Buy' rating.
The raised price target indicates the analyst's increased confidence in the company's future performance. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100